What was the physiological, safety, and compliance rationale for combining basal insulin plus GLP-1 RA into a fixed ratio formulation? How does this achieve pan-glycemic (FBG and PPG) control?

What was the physiological, safety, and compliance rationale for combining basal insulin plus GLP-1 RA into a fixed ratio formulation? How does this achieve pan-glycemic (FBG and PPG) control?

What was the physiological, safety, and compliance-focused rationale for combining basal insulin plus GLP-1 RA into a fixed ratio formulation? How would this approach achieve pan-glycemic (FBG and PPG) control?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Juan Frias, FACE, MD

Juan Frias, FACE, MD

Clinical Assistant Professor of Medicine
University of California
San Diego, California
Chief Medical Officer
National Research Institute
Los Angeles, California